Clinical study "common" name (formal title)	Number of enrollees (per protocol [PP]/intent-to-treat [ITT])	Funding source (pharmaceutical company/National Institutes of Health [NIH])	Year completed	Primary publication	Full study treatment protocol
EVEREST (Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy)	61 Asian patients	Novartis Pharma NCT00674323	2009	Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-1464. https://journals.lww.com/retinajournal/Abstract/2012/09000/EVEREST_STUDY__Efficacy_and_Safety_of_Verteporfin.4.aspx